Evidence map›Paper›PMID 40428998›Full record

ReviewMaterials (Basel, Switzerland)2025

Ti-Based Metallic Biomaterials for Antitumor Applications.

Xiang Yan, Hui Liu, Zhe Zhang, Xiang Deng, Manfeng Lin, Zongyuan Cai, Dongying Tang, Hang Wang, Wen Liu, Dapeng Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiang YanSchool of Information and Intelligent Engineering, Zhejiang Wanli University, Ningbo 315100, China.
Hui LiuCollege of Biology, Hunan University, Changsha 410082, China.
Zhe ZhangCollege of Biology, Hunan University, Changsha 410082, China.
Xiang DengCollege of Biology, Hunan University, Changsha 410082, China.
Manfeng LinCollege of Biology, Hunan University, Changsha 410082, China.
Zongyuan CaiCollege of Biology, Hunan University, Changsha 410082, China.
Dongying TangCollege of Biology, Hunan University, Changsha 410082, China.
Hang WangSchool of Information and Intelligent Engineering, Zhejiang Wanli University, Ningbo 315100, China.
Wen LiuSchool of Information and Intelligent Engineering, Zhejiang Wanli University, Ningbo 315100, China.
Dapeng ZhaoCollege of Biology, Hunan University, Changsha 410082, China.ORCID 0000-0001-6777-7760

Funding

National Key R&D Program of China 2024YFB3815004National Natural Science Foundation of China 52171114
6 · The paper itself

Abstract

Titanium (Ti)-based metallic biomaterials (MBs) are traditionally employed as mechanical supports and constraints in clinical practice, owing to their superb comprehensive mechanical properties, great corrosion resistance, and good biocompatibility. Recently, Ti-based MBs have emerged as promising candidates for antitumor applications. These developments focus on the functionalization of Ti-based MBs to inhibit tumor propagation and recurrence. This work systematically examines the antitumor approaches of Ti-based MBs and categorizes them into physical and chemical approaches. Physical strategies, such as the photothermal and photocatalytic techniques, are usually related to material-specific properties. Chemical approaches often employ controlled local drug delivery (LDD) systems. Ti-based LDD systems enable the targeted release of chemotherapeutics, metal ions, or immunomodulatory agents at tumor sites. This review highlights the efficacy of these surface-functionalized Ti-based MBs against diverse tumors. Additionally, the challenges and prospects of antitumor Ti-based MBs are also discussed.

Indexed as

antitumorlocal drug deliveryphotodynamic therapyphotothermal therapyTi-based metallic biomaterials

Identifiers

PMID40428998
PMCPMC12113515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.